Atopic Eczema: Dupilumab Dosing Study

We are studying how different dosing schedules of dupilumab affect people with controlled atopic eczema. The goal is to see which schedule works best for managing symptoms and improving quality of life.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Dupixent
Dupixent is a medicine used to treat eczema and certain asthma symptoms.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Dupilumab
Dupilumab is a substance that reduces allergic inflammation to treat moderate-to-severe eczema, some asthma, and nasal polyps.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Amsterdam UMC
Dermatology
Abcoude, Netherlands
Flevoziekenhuis Stichting
Dermatologie
Almere Stad, Netherlands
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Dermatology
Rotterdam, Netherlands
Sponsor: Amsterdam UMC
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.